A novel small‐molecule BI‐44 was synthesized, which suppressed BMI1/MCL1 expression and showed significant anti‐tumour effect in preclinical models, providing a new and promising approach for NSCLC treatment. This evidence concerns the gene MCL1 and neoplasm.